Your browser doesn't support javascript.
loading
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu, Xiaofei; Cao, Yangsen; Liu, Wenyu; Ju, Xiaoping; Zhao, Xianzhi; Jiang, Lingong; Ye, Yusheng; Jin, Gang; Zhang, Huojun.
Afiliação
  • Zhu X; Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
  • Cao Y; Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
  • Liu W; Department of Hepatobiliary and Pancreatic Surgery, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
  • Ju X; Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
  • Zhao X; Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
  • Jiang L; Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
  • Ye Y; Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
  • Jin G; Department of Hepatobiliary and Pancreatic Surgery, Changhai Hospital affiliated to Naval Medical University, Shanghai, China. Electronic address: jingang@hotmail.com.
  • Zhang H; Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China. Electronic address: chyyzhj@163.com.
Lancet Oncol ; 22(8): 1093-1102, 2021 08.
Article em En | MEDLINE | ID: mdl-34237249

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Piridonas / Pirimidinonas / Terapia Combinada / Carcinoma Ductal Pancreático / Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Piridonas / Pirimidinonas / Terapia Combinada / Carcinoma Ductal Pancreático / Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2021 Tipo de documento: Article